Abstract 'Immune checkpoint blockade'for cancer describes the use of therapeutic antibodies
that disrupt negative immune regulatory checkpoints and unleash pre-existing antitumour …

Breast cancer is the most commonly diagnosed cancer in women and is a leading cause of
cancer death in women worldwide. Despite the significant benefit of the use of conventional …

Introduction Immune checkpoint inhibitor-related pneumonitis (ICIP) is a potentially life
threatening immune-related adverse event (irAE), especially in non-small cell lung cancer …

Background Despite recent advances, outcomes in patients with relapsed/refractory diffuse
large B-cell lymphoma (DLBCL) remain poor. Immune checkpoint inhibitors have shown …

Neutrophils dominate the immunological landscape of multiple types of solid tumours in
mice and humans and exert different pro‐or antitumoral activity. This functional …

Background The high incidence and mortality of lung cancer have seriously affected human
life and health. Nivolumab is a monoclonal antibody that can inhibit programmed death 1 …

Talimogene laherparepvec (T‐VEC) is a intralesional oncolytic virotherapy, licensed in the
European Union for locoregional advanced melanoma of American Joint Committee on …

Background: In this meta-analysis, we compared the clinical efficacy and safety of
ipilimumab/nivolumab combination therapy with those of ipilimumab monotherapy for stage …

Background Cancer, with sustained high mortality, is a worldwide threat to public health.
Despite the survival benefit over conventional therapies shown in immune checkpoint …

The recent therapeutic success of immune checkpoint inhibitors in the treatment of
advanced melanoma highlights the potential of cancer immunotherapy. Oncolytic virus …